MedTrace Logo

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

NCT06441669 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-06-04

No results posted yet for this study

Summary

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation

Conditions

  • Cytomegalovirus Infection Reactivation

Interventions

DRUG

Letermovir

Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Xiaoyu Zhu, ph.D · The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2026-05-01
Completion
2026-05-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441669 on ClinicalTrials.gov